SUO 2018: The Microbiome in Kidney Cancer

Phoenix, Arizona ( Dr. Pal gave an excellent talk on the role of the microbiome in kidney cancer. He began his talk stating that the last year was replete with exciting new studies, including Checkmate 214 showing the advantage of the combination of two immunotherapy drugs over sunitinib in patients with advanced or metastatic renal cell carcinoma (RCC), Javelin 101 and Immotion 151, demonstrating the advantage of the combination of a VEGF inhibitor and immunotherapy drug over sunitinib, and the CABOSUN trial demonstrating the known advantage of a VEGF inhibitor over sunitinib. This leads us to ask whether biomarkers, such as the microbiome, can elucidate and help us choose the most appropriate treatment strategy.

SUO 2018: Bladder Cancer and the Microbiome: Emerging Evidence

Phoenix, Arizona ( Dr. Steinberg presented in his talk the role of the microbiome in bladder cancer. The microbiome consists of all the bacteria, viruses, and fungi that coexist within our body. There are complex interactions with host cells and immune system. The microbiome may be altered by dietary, and environmental factors.

SUO 2018: Lynch Syndrome: Diagnosis, Screening and Management

Phoenix, Arizona ( Dr. Matin discussed updates in Lynch Syndrome diagnosis, screening and management. Lynch syndrome, also known as hereditary non-polyposis colon cancer, is caused by an autosomal dominant germline mutation in one of several DNA mismatch repair genes (MLH1, PMS2, MSH2, MSH6). Expressions of each gene can be confirmed using tissue immunohistochemistry where absence of >1 is indictive of Lynch Syndrome.

SUO 2018: Circadian Fluctuations of the Gut Microbiome and Host Physiology

Phoenix, Arizona ( In this talk, Dr. Zarrinpar, a gastroenterologist, focused on the circadian fluctuations of the gut microbiome and host physiology. He started by briefly reviewing the impacts of time-restricted feeding (TRF):

SUO 2018: Fasting Regimens and Metabolic Health

Phoenix, Arizona (  There are numerous fasting regimens out there, Dr. Ruth Patterson's research and reviews distill them down to the following 4 that may have an impact on health outcomes. These include alternate-day fasting, modified fasting regimes, time-restricted feeding, and religious fasting.

SUO 2018: Impact of Time-Restricted Feeding on Cancer Risk in Mice

Phoenix, Arizona ( Dr. Sears is one of the leading researchers in the field of TRF in an in-vitro setting, and her studies on mouse models (amongst others) are integral to the basis of the translational work being done in the field.

SUO 2018: Impact of Food Intake Timing on Metabolic Health and Cancer Risk in Humans

Phoenix, Arizona ( In the session, "Fasting Interval, Metabolism, and Cancer Risk", Dr. Marinac focused on the clinical impact of food intake timing on metabolic health and cancer risk in humans. The premise is that timed restricted fasting (TRF), which she labels nightly fasting, may be associated with and relevant to multiple obesity-related cancers (seen below), as well as loosely associated with others, such as prostate cancer.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.